BRAF and neoplasm: Fifteen patients with BRAFV600E mCRC were treated with vemurafenib (BRAF inhibitor) and panitumumab, and 10 of 12 evaluable patients showed some tumor regression with two patients showing a partial response and stable disease lasting more than 6 months [84].